Nasdaq Extends Exicure's Deadline to December 2 for Restoring Stockholders' Equity Compliance
XCUR sits 24% above its 52-week low of $1.05.
Summary
Nasdaq granted Exicure an extension until December 2, 2026 to regain compliance with the minimum stockholders' equity listing rule. The company remains at risk of delisting if it fails to meet the deadline.
Key Events · Legal and Risk Events · XCUR
-
Nasdaq Extension Granted
Nasdaq granted Exicure an extension through December 2, 2026 to regain compliance with Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity.
-
Compliance Deadline Set
The company must publicly demonstrate compliance with the stockholders' equity requirement on or before December 2, 2026, with Nasdaq monitoring through the next periodic report.
-
Delisting Risk Remains
The extension does not constitute a determination of compliance. If Exicure fails to satisfy the terms, Nasdaq may issue a delisting determination, which the company could appeal to a Hearings Panel.
-
Financial Distress Context
The Q2 2026 10-Q disclosed cash of $1.7 million, stockholders' equity below the Nasdaq minimum, and a going concern warning, underscoring the urgency of the compliance initiatives.
Analysis · XCUR · Life Sciences
Exicure has been granted an extension by Nasdaq through December 2, 2026 to regain compliance with the $2.5 million minimum stockholders' equity requirement. The company's Q2 10-Q revealed equity below the Nasdaq minimum and a going concern warning, leaving a short runway to complete compliance initiatives. Failure to meet the deadline could lead to a delisting determination, which the company could appeal.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.7% of the 1745 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XCUR was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5M. The 52-week trading range was $1.05 to $9.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.